Skip to main content
. 2023 Sep 29;57(3):359–366. doi: 10.14744/SEMB.2023.51437

Table 2.

Comparison of demographic and baseline characteristics of patients in low-dose vs. standard-dose thrombolytic therapy groups

Low-dose, n=19 (17.4%) Standard-dose, n=90 (82.6%) Test statistic Total, n=109 p
Age (years)
>65
68 (42–91)/47.74
12 (63.2)
74 (35–92) /56.53
63 (70)
717
0.09
73 (35–92)
75 (68.8)
0.27a
0.75b
Gender, n (%)
Female
Male

8 (42.1)
11 (57.9)

46 (51.1)
44 (48.9)

0.21

54 (49.5)
55 (50.5)

0.64b
Vascular risk factors, n (%)
Hypertension
Diabetes
Hyperlipidemia
Atrial Fibrillation
CAD
Smoking

13 (68.4)
2 (10.5)
7 (36.8)
9 (47.4)
4 (21.1)
5 (26.3)

59 (65.6)
30 (33.3)
24 (26.7)
41 (45.6)
24 (26.7)
33 (36.7)

.00
3.93
0.37
0.00
-
0.35

72 (66.1)
32 (29.4)
31 (28.4)
50 (45.9)
28 (25.7)
38 (34.9)

1b
0.08b
0.54b
1b
0.77c
0.55b
SBP (mmHg) 146 (115–220)/53.68 150 (80–200)/55.28 830 150 (80–220) 0.84a
DBP (mmHg) 85 (70–120)/65.74 80 (60–120)/52.73 651 83 (60–120) 0.09a
Blood glucose level (mg/dL) 127 (97–194)/ 51.26 132 (78–363)/ 55.79 974 130 (78–363) 0.57a
Acetyl salicylic acid use, n (%) 5 (26.3) 22 (24.4) - 27 (25) 0.54c
History of stroke 2 (10.5) 4 (4.4) - 6 (5.5)22 0.28c
Clinical stroke type, n (%)
TACI
PACI
POCI
Lacunar

8 (42.1)
9 (47.4)
1 (5.3)
1 (5.3)

46 (51.1)
32 (35.6)
6 (6.7)
6 (6.7)

1.52

54 (49.5)
41 (37.6)
7 (6.4)
7 (6.4)

0.67d
S/N time (min) 150 (79–270)/59.63 150 (60–270)/54.02 767 150 (60–270) 0.48a
NIHSS (pre-treatment) 12 (3–20)/42.29 15 (5–26)/57.68 613 14 (3–26) 0.053a

CAD: Coronary artery disease; DBP: Diastolic blood pressure; Min.: Minimum; Max.: Maximum; NIHSS: The national institutes of health stroke scale score; S/N: Symptom/needle; SBP: Systolic blood pressure; TACI: Total anterior circulation infarct; PACI: Partial anterior circulation infarct; POCI: Posterior circulation infarct; Data were expressed as median (minimum: maximum)/mean Rank and n (%); a: Mann Whitney U Testi; b: Continuity correction; c: Fisher’s Exact Test; d: Pearson Chi-Square.